MOTS-c vs Retatrutide
A side-by-side research comparison of MOTS-c and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MOTS-c | Retatrutide |
|---|---|---|
| Full name | Mitochondrial Open Reading Frame of the 12S rRNA-c | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Activates AMPK pathway, enhances mitochondrial metabolism, improves insulin sensitivity by increasing GLUT4 translocation, and promotes fatty acid oxidation. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 2,175 Da | 5,200 Da (approximate) |
| Half-life | 4-8 hours | 6 days |
| Bioavailability | Moderate (SubQ) | High (SubQ) |
| Typical dose | 5-10 mg | 1-2 mg → titrate up to 12 mg |
| Frequency | 3-5x per week | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
MOTS-c reported benefits
- Exercise mimetic effects
- Improved insulin sensitivity
- Enhanced fat oxidation
- Metabolic homeostasis
- Anti-aging metabolic benefits
- AMPK activation
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.